Publications by authors named "S N Teraoka"
Importance: Heterogeneity in development of estrogen receptor (ER)-specific first primary breast cancer exists due to deleterious germline variants in moderate- to high-penetrance breast cancer susceptibility genes, but it is unknown if these associations occur in ER-specific CBC.
Objective: To determine the association of deleterious germline variants in breast cancer susceptibility genes with ER-specific CBC development and whether ER status of the first primary breast cancer modifies these associations.
Design, Setting, And Participants: This case-control study included CBC cases and matched unilateral breast cancer controls from The Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study, a population-based case-control study.
Background: In Japan, since 2014, new treatments such as androgen receptor signaling inhibitors and cabazitaxel have become applicable for metastatic castration-resistant prostate cancer (mCRPC), leading to dramatic changes in treatment options.
Objective: This study aims to evaluate the impact of recent advancements in treatment options on the overall survival (OS) of patients diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC) in Japan.
Methods: A retrospective analysis was conducted on 2450 Japanese men diagnosed with de novo mCSPC between 2008 and 2018.
Article Synopsis
- The AminoIndex™ Cancer Screening (AICS breast) test utilizes plasma free amino acid profiles to aid in breast cancer detection, with a study focusing on its correlation with breast density observed through mammograms (MMG).
- Analysis included preoperative mammograms and blood samples from 224 breast cancer patients, showing differing detection rates between MMG and AICS based on breast density classifications.
- The results indicated that while the detection rate for MMG decreased in patients with dense breasts, AICS maintained consistent detection across all breast densities; combining both methods significantly improved overall detection rates.
Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus bevacizumab or osimertinib monotherapy in previously untreated patients with advanced -positive nonsquamous NSCLC.
Methods: We previously reported the primary results of a randomized, open-label, phase 2 study comparing osimertinib plus bevacizumab with osimertinib monotherapy for this population.
Article Synopsis
- Immune-related adverse events (irAEs) can influence the effectiveness of PD-L1 inhibitors in treating metastatic non-small cell lung cancer (NSCLC), but their impact on nonmetastatic NSCLC outcomes was previously unclear.
- This study evaluated the relationship between irAEs and progression-free survival (PFS) in Stage III NSCLC patients undergoing treatment with the PACIFIC regimen, analyzing both mild and nonmild irAEs through robust statistical methods.
- Findings indicated that patients with nonmild irAEs experienced poorer PFS compared to those with mild irAEs or none at all, suggesting that mild irAEs could indicate better survival outcomes while more severe reactions treated with steroids are linked to worse outcomes.